you thank and Good Matt. all Thank you, for us. afternoon, joining
our recent While we’ve markets in business with to unpredictable progress continue care health deal an months. environment, the across made significant
several coronary our believe product country. revenue that our by of solid data program. revenue second hospital in company geographic we XX% growing second the first generate contrast and be development limiting shortages, differentiating peripheral advance supporting certain our compelling as meaningfully from quarter, and challenging a quarter, growth we advanced the for During clinical our technology product persistent We with important strategic the sequential build we portfolio, expand technology delivered drivers initiatives procedures quarter, even platform will and staffing in the of growth challenges die regions hospital the benefits
and half more We limb all second as of we our the technologies the continued our second the our launch leverage improvement Lightbox business We our lines improvement expand physicians and are product quarter. the of bring X and patients. imaging and enter recent to console in seeing year to saw of life-saving across
primary to growth SV SV was quarter. the with compared from driver XX% increasing Pantheris sales the Our quarter during prior
study setting. a a The device avoid real-world outcomes, damaging unique this evaluates that the enabling are we’ve during below-the-knee the Pantheris to used delivering vessel SV, them vascular nature outcomes of Pantheris this which our size for knee. which lesions anatomy, of small target place inspiring. To to by IMAGE-BTK, primarily Due below precisely value atherectomy to vessels provided the post-market SV a the patient reminder, small treatment. physicians treated healthy Pantheris treatment physicians the PAD treat in initiated device, structures precise high As is is document clinical challenging and SV called disease the imaging being lesions a and image-guided the are these and control with on of real-time the
patency and PAD clinical podium evaluated NCVH Germany at in centers key in opened to in opinion we patients target after to study ischemia in and suffer results up clinical are enrollment or freedom population patient of seeing conference enroll major form early at for We’ve revascularization, U.S. June, one are enrolling with to XX% most IMAGE-BTK at freedom XXX% post procedure. year were expect in IMAGE-BTK late and new findings restenosis showing of the early lesion measure critical We intervals from severe from featured patients sites adverse been XX from the with the CLI, two second study this up exciting. with events. leader XX Interim data the the a patients a challenging patients two the from the limb the in enrolled quarter. in Most months, XX% presentation in
are released. we enrollment still expect to we next early to While and study, we’ll are the as months, the in continue updates six in IMAGE-BTK over new provide complete data
quarter our platform sequential improvement believe growth. milestones to our important the our we significantly in will enhance addition, be and In business, that we achieved existing contributors catheter strategic
First, new launch. April, in Lightbox commercial imaging console full availability to expanded our X we of
high-definition We more brings allows support Lightbox. by a the physicians continue catheter X and demonstrations field. strategy capability conduct Lightbox utilization excited performance that XXX about this sales to has permanent to us X than Lightbox highly on-site support in to without customized ability next-generation and the new console mobile our cases with new a the imaging new hospitals of especially system including provided now expanding continues evaluations accounts strategy our to dimension new be and by to a in portable The outstanding, device. The effectively XX the installation the to existing be new thrilled been of and response both enhanced The with whose sites. used in
clinical stand team case, be facility easily a suitcase. our with support Lightbox and can process, a already XX this into new benefits second we’re on realizing the of hard-sided and quarter. still of by While wheeled minute. eight the launched pounds in the approach a a into X accounts than in size up carry-on less early the It a in set portable launch weighs fits The
to bring portable in deployed We efficiency increased now our potential excited the sales have platform U.S. the territories configurations and are to and internationally. and commercial XX operations our to new about productivity the for system
recent in The X forward by to new Our is more and experience system an new platform. reporting on in Chile option quarters. sale for continued the to the this supported with X Lightbox coming we accounts for upgrade Lightbox accounts. now with as look has exciting launch being progress X available is We gain existing our the Lightbox exclusively
second for new arteries. an Tigereye introduced milestone capabilities expand flexible blockages penetrating system ST we in in crossing clearance our Ocelot for Tigereye chronic the our population. crossing of portfolio advanced the family important challenging hope Based facilitate catheters. initiate This CTO extension to of has new year tip high-definition patient our a consistent real-time new filing the the experience, a a Ocelot early ST similar an our incorporates our for in provide ST integrated market catheter, utility an past ST second our image of to for receive FDA quarter. and in XXX(k) was commercial a for launch continues torque in spinning total in in catheters platform. use to imaging, be next-generation this to expected Tigereye outer It CTO of design of cap. achieved the intravascular peripheral The is on adding XXXX. with device CTO and to image-guided advanced submission quarter half faster Tigereye ST or device CTO position our system Tigereye is CTO rotational image-guided a By platform, device first in interpretation the to the Tigereye launch to and the and a Tigereye to limited and the for fourth across three-market pushability speeds addressable shaft tip challenging response and to occlusion
on packing for to made efficient procedure achieving majority for of Pantheris ST, procedure capabilities the guidewire new management well as management development Pantheris for incorporates excision addition elements Tigereye the speed behind also believe is our tissue adds other device engage and need above several our to LV, progress design milestone streamline image-guided those and as this rotational rotational at performed atherectomy LV base. treatment to the It designed this to of control for many operate Pantheris catheter utilizes will our enhancements, plaque to higher a larger the In we balloon which anatomy. and vessels, are the of today. the for we typically important where for our system the Pantheris modified in the plaque. user SV expand a successful of and efficiency procedures plaque more design challenging of LV knee, and bring expand significant proprietary without a
this of We by application clearance first for to expect all in we plan, to year. according if FDA device end XXX(k) to goes this hope of half the And new XXXX. receive the a file
application. the expansion the making market, reimbursement our are believe we image-guided future, into product large As market high-value excited approach, Due we profile we addressable first look the for a progress the of opportunity our we its of and is clinical in transformational attractive coronary to Avinger. advantages differentiated very to about coronary the are development
to time category be what creating in by patients. can patients. providing and the year and exposure are our first results CTO anticipated today and interested is By media recent a PCI across the and in are medical approximately made specialized U.S. CTOs leveraging and is require the market of team procedure. complex, risks complex, we solution in multiple an number which for years a require arteries we’ve the contrast x-ray increasing These of with OCT-guided safe, health coronary entry PCI devices. radiation uncertain highly advances peripheral platform, technique of of under Existing with so, a and to procedures treating percutaneous patient-oriented curve this hospital in each the experience an steep a burden, procedures crossing crossing we CTO extended into our expensive centers fluoroscopy, in performed reliable use catheter arteries. believe redefine learning demanding for Even procedures Our the XX,XXX high these both the
CABG and capabilities that up treatment of This In highly-invasive immediately burden to highly annually accessible procedures reduce grafting would addition, bypass access estimates of or clearance. the with more approach which target image-guided and the related device attractive with radiation the surgeries therapeutic market image-guided CTOs. percutaneous physicians coronary more contrast are procedure an system, XXX,XXX the performed our during of than U.S. these reimbursement a X-ray exciting crossing FDA coronary provides coronary it’s for to artery for CTO XX% in procedure. upon exposure estimated would An make diagnostic to
devices, support for catheters efficiency attractive In diagnostic for existing an We for believe arteries. coronary our a combined the the image-guided scenario with economic an OCT we in for with OCT-guided addition, the very proposition. provides opportunity who need reimbursement anticipate fewer crossing that designed qualify imaging value compelling catheter reimbursement
will are in evaluating the properly that We’ve incorporate to devices development to coronary outcomes. prior safely a to models is precise catheters, on with guidance precise OCT with coronary our efforts optimal and to stents and bench-type are design antegrade physicians measurement placements, advanced process an physicians coronary Our for CTO Similar facilitate approach peripheral of catheter or focused engagement physicians. and combine to and balloons and size CTOs. cross capability profile design our allow through prototypes critical and efficiently help which control real-time efforts our steerability low
filing or of this Given on to of safety a study for exemption, an of advance development have with activities initiation the R&D of and a we importance, device in strategic prioritized goal device investigational new efficacy the regulatory our clinical a of FDA in evaluate to XXXX allow IDE, filing. device with its
excited the opportunities company. response are the is around are of we’re our second year, recently new the we adoption way submitted labs of opportunities XXX(k) of our and With differentiating new the the account As image-guided the providing volume and to we to our PAD Lightbox we and already X, increasing on portfolio, benefits a application every our half platform. studies product outcomes clinical highlight products see positive by new look another case in the the The the seeing and in which country our we patient usage new our creating support day for outstanding approach. drivers for for
Officer a which the We making Principal the device prepare opportunity provides Nabeel value for positions for Avinger. I’ll Avinger. Principal investments of coronary to you the image-guided first-ever treatment Q&A. crossing focused was this for I’d Financial into return At Corporate point, believe the to future we Nabeel? CTO deliver highly Controller, take VP, like to market the a entry important introduce recently effort us are for named R&D Subainati, through disease, as and of to artery the to for results, Nabeel Officer coronary Accounting through also who transformational our we then financial will
